Health
your username
January 13, 2021
Yesterday, Pfizer Inc., C.P. Pharmaceuticals International C.V., PF PRISM C.V., PBG Puerto Rico LLC, and PF PRISM IMB B.V. (collectively, Pfizer) filed suit against Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (collectively, Aurobindo) in the District of Delaware. The patent infringement complaint contends that the filing of Aurobindo’s Abbreviated New Drug Application (ANDA) seeking U.S. Food and Drug Administration (FDA) approval to sell generic copies of two different dosages of Pfizer’s Xeljanz tablets is illegal.
The filing explains that the active ingredient in Xeljanz is tofacitinib citrate. The drug is used to treat adults with certain forms of rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis and children 2 years and older with certain manifestations of juvenile idiopathic arthritis. Pfizer’s two patents-in-suit reportedly cover claims relating to Xeljanz’s formulation.
Health
your username
December 24, 2020
Merz Pharmaceuticals, LLC and Merz North America, Inc. (together Merz) filed a civil complaint against defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc. (together Aurobindo) on Wednesday. The action relates to Aurobindo’s filing of an Abbreviated New Drug Application (ANDA) seeking Food and Drug Administration (FDA) approval to manufacture and sell a generic version of the plaintiffs’ trademarked Cuvposa, a drug that treats sialorrhea, a condition which causes drooling or excessive salivation. Merz seeks a permanent injunction blocking Aurobindo from bringing the generic to market before the expiration of the two patents-in-suit.
According to the complaint, the Merz plaintiffs are North Carolina businesses that hold intellectual property and regulatory approval rights for “innovative pharmaceutical products,” and also develop, market, and sell them. The filing states that generic manufacturer Aurobindo Pharma Ltd. is bel